Literature DB >> 33901582

Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives.

Aline Martins Dos Santos1, Suzana Gonçalves Carvalho2, Andréia Bagliotti Meneguin2, Rafael Miguel Sábio2, Maria Palmira Daflon Gremião2, Marlus Chorilli3.   

Abstract

Colon-targeted oral delivery of drugs remains as an appealing and promising approach for the treatment of prevalent intestinal diseases (ID), such as inflammatory bowel disease (IBD) and colorectal cancer (CRC). Notwithstanding, there are numerous challenges to effective drug delivery to the colon, which requires the design of advanced strategies. Micro- and nanoparticles have received great attention as colon-targeted delivery platforms due to their reduced size and structural composition that favors the accumulation and/or residence time of drugs at the site of action and/or absorption, contributing to localized therapy. The choice by natural polysaccharides imparts key properties and advantages to the nano-in-microparticulate systems to effective colon-specific oral delivery. This review proposes to discuss the physiological barriers imposed by the gastrointestinal tract (GIT) against oral administration of drugs, as well as pathological factors and challenges of the ID for oral delivery of colon-targeted systems. We then provide an updated progress about polysaccharides-based colon-targeted drug delivery systems, including microparticulate, nanoparticulate and nano-in-microparticulate systems, highlighting their key properties, advantages and limitations to achieving targeted delivery and efficacious therapy within the colon. Lastly, we provide future perspectives, towards advances in the field and clinical translation of colon-targeted oral delivery systems for ID therapy.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Colon-targeted drug delivery; Colorectal cancer; Crohn's disease; Inflammatory bowel disease; Micro/nanoparticulate systems; Oral administration; Polysaccharides; Ulcerative colitis

Year:  2021        PMID: 33901582     DOI: 10.1016/j.jconrel.2021.04.026

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  5 in total

1.  Oral Administration of Therapeutic Enzyme Capsule for the Management of Inflammatory Bowel Disease.

Authors:  Xiao Liang; Kai Wen; Yingxuan Chen; Guangxu Fang; Shengcai Yang; Quanshun Li
Journal:  Int J Nanomedicine       Date:  2022-10-17

2.  GelNB molecular coating as a biophysical barrier to isolate intestinal irritating metabolites and regulate intestinal microbial homeostasis in the treatment of inflammatory bowel disease.

Authors:  Qijiang Mao; Haoqi Pan; Yiyin Zhang; Yi Zhang; Qiuwen Zhu; Yi Hong; Zhengze Huang; Yang Li; Xu Feng; Yifeng Fang; WenChao Chen; Pengfei Chen; Bo Shen; Hongwei Ouyang; Yuelong Liang
Journal:  Bioact Mater       Date:  2022-04-21

Review 3.  Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges.

Authors:  Shangyong Li; Hui Zhang; Kaiwei Chen; Mengfei Jin; Son Hai Vu; Samil Jung; Ningning He; Zhou Zheng; Myeong-Sok Lee
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

Review 4.  Nanotechnology for research and treatment of the intestine.

Authors:  Yanquan Fei; Yong Ma; Huaizu Zhang; Hao Li; Guangfu Feng; Jun Fang
Journal:  J Nanobiotechnology       Date:  2022-09-29       Impact factor: 9.429

5.  Colonic Delivery of Celastrol-Loaded Layer-by-Layer Liposomes with Pectin/Trimethylated Chitosan Coating to Enhance Its Anti-Ulcerative Colitis Effects.

Authors:  Jing Xian; Xuemei Zhong; Huan Gu; Xiao Wang; Jiaxin Li; Jingjing Li; Yihan Wu; Chen Zhang; Jinming Zhang
Journal:  Pharmaceutics       Date:  2021-11-25       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.